KALV KalVista Pharmaceuticals, Inc.: institutional ownership and insider trading
11 funds reported holding $42.2M of KalVista Pharmaceuticals, Inc. in their latest 13F filings; in Q2 2026 funds net sold $1.95B, with 1 new positions and 183 funds selling out; over the last 12 months insiders bought $0 and sold $7.07M on the open market.
KALV revenue and earnings
- Quarter ended Mar 31, 2026: revenue $40.9M, net income −$23.5M, EPS -0.43
- Quarter ended Sep 30, 2025: revenue $13.7M, net income −$49.5M, EPS -0.92
- Quarter ended Jul 31, 2025: revenue $1.40M, net income −$57.6M, EPS -1.12
- Quarter ended Mar 31, 2025: revenue n/a, net income −$51.8M, EPS -0.98
Largest institutional holders of KALV
- VANGUARD GROUP INC — $40.5M
- Nuveen Asset Management, LLC — $681K
- HAP TRADING, LLC — $457K
- JANUS HENDERSON GROUP PLC (JHG) — $220K
- SHERBROOKE PARK ADVISERS LLC — $184K
- Martin Worley Group — $115K
- CWM, LLC — $18.1K
- COMERICA BANK — $8.38K
- Lindbrook Capital, LLC — $3.06K
- Parkworth Wealth Management, Inc. — $249
Recent KALV insider trades
- May 27, 2026: Yea Christopher sold 33,800 shares ($905K)
- May 26, 2026: Yea Christopher sold 1,966 shares ($52.6K)
- May 26, 2026: Sweeny Nicole sold 1,489 shares ($39.9K)
- May 26, 2026: Audhya Paul K. sold 2,239 shares ($60.0K)
5%+ owners
- SilverArc Capital Management, LLC: 5.6% (Schedule 13G, filed May 13, 2026)